Nephros (NASDAQ:NEPH) used an investor event to outline its strategy for expanding beyond filtration products into a broader water-quality platform built around products, services and education.
Robert, who led the event for Nephros, said the company’s purpose is to “purify water where it matters most,” including hospitals, dialysis clinics, commercial buildings, laboratories and food service environments. He said customer concerns have broadened from Legionella to include opportunistic premise plumbing pathogens, biofilm, antibiotic-resistant organisms, PFAS, lead, aging infrastructure and micro- and nanoplastics.
Education and Services Take Larger Role
Brianne, speaking on Nephros’ education efforts, said the company’s “because water matters” rebrand led it to make education a cornerstone of its customer strategy. She said changing regulations, standards and water-quality risks are creating compliance and operational challenges, particularly for healthcare and other regulated industries.
Brianne said the Nephros Water Institute, launched earlier this year, formalizes the company’s work through webinars, tailored resources, industry engagement and evidence-based education. She said the effort is intended to help customers understand risks before they purchase products and to support better implementation after purchase.
Robert said Nephros is also investing in services because many customers need help with installation, sanitization, replacement and maintenance. He said service contracts can create more predictable recurring revenue while helping ensure the filters perform as intended.
Partner Highlights Emergency Response
Mike Kennedy of Total Quality Medical said his company has worked with Nephros since 2008, “maybe even earlier,” initially supporting refurbished reverse osmosis systems and later becoming one of Nephros’ early distributors. Kennedy said the relationship helped Total Quality Medical expand from dialysis equipment into hospitals and infection-control products.
Kennedy also described a recent urgent request in which Nephros prepared and shipped filters overnight for delivery in New York by 8 a.m. the next morning, despite the purchase order arriving late in the process.
R&D Focuses on Custom and OEM Applications
Michael Milman, vice president of R&D, said Nephros’ technology originated from the company’s early work developing a dialysis system that required high-purity water. He said that foundation remains central to many of the company’s current products.
Milman said Nephros works with OEM partners early in the development process to understand the problem a customer is trying to solve, rather than simply supplying a requested filter. He said the company supports customers through development, launch and post-launch engineering.
Milman described applications ranging from infection control and dialysis to pathogen detection, military filtration, food processing, medical device manufacturing, dental applications and laboratory water. He said Nephros uses hollow fiber ultrafiltration and microfiltration, as well as media filters for contaminants such as PFAS, lead, chlorine and chloramine.
He also said Nephros’ experience with FDA-cleared products can help customers navigating regulatory pathways. In some cases, Milman said existing biocompatibility testing and third-party validations could shorten customer development cycles by six to 12 months.
Quarterly Financial Update
Judy provided a recap of first-quarter results, saying revenue was $5.2 million, up 7% year over year. She said growth was driven by programmatic revenue of more than 20%, which offset a year-over-year decline in the company’s emergency response business. Revenue increased 10% sequentially from the fourth quarter to the first quarter, driven by programmatic and service revenue.
Gross margin declined to 57% from 65% in the first quarter of 2025. Judy cited several factors, including tariffs, foreign exchange, customer mix and business mix. She said tariffs cost the company more than $200,000 in the first quarter of 2026, and without that impact, gross margin would have been “comfortably in the low 60s percentages.”
Judy said Nephros has applied for a refund on tariffs paid through February and expects to receive it “in the very near future.” She said the tariff rate on products imported from Italy was reduced from 15% to 10% at the end of February, with the current tariff round scheduled to expire at the end of July.
Research and development expense increased 17% year over year due to higher headcount, while SG&A expense increased 12% due to compensation costs and higher professional fees. Net income declined to $140,000 from $558,000 a year earlier. Cash at the end of March was $4.1 million, down from $5.4 million at year-end, reflecting higher accounts receivable and a $400,000 increase in inventory.
Outlook and Investor Questions
During the Q&A, Robert said Nephros does not expect the lower first-quarter gross margin to be permanent and is working to return margins to the 60% range. He also said emergency response revenue has become a smaller portion of the business as programmatic revenue grows.
Robert said Nephros is pursuing growth beyond healthcare in areas such as government buildings, correctional facilities, universities, schools, airports, dental and other commercial uses. He clarified that a recently discussed geographic initiative was in Puerto Rico, not Mexico, and said the company has added local support and Spanish-language materials for that market.
Judy said Nephros has a solid balance sheet, no debt and more than $4 million in cash at the end of March. She said the company could use its balance sheet for strategic growth initiatives, including potential acquisitions, merger partners or business development opportunities.
Robert said artificial intelligence is currently viewed as a productivity tool at Nephros, used for areas such as content development, engineering research, customer communications and software development. He said AI could eventually support customer tools such as predictive maintenance or water-quality analytics, though it is not currently a product strategy.
About Nephros (NASDAQ:NEPH)
Nephros, Inc is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.
The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems.
